Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin Uptakes: A comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 4, 2004, Pages 411-421

  Le Jeune, Nathalie ^a   Perek, Nathalie ^a   Denoyer, Delphine ^a   Dubois, Francis ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Cholesterol; Glutathione (GSH); Malignant glioma; MRP1; Tc 99m sestamibi (MIBI); Tc 99m tetrofosmin (TFOS)

Indexed keywords

ACETYLCYSTEINE; CHOLESTEROL; CHOLESTEROL ESTER; GLUTATHIONE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; TETROFOSMIN TC 99M; TRACER;

ARTICLE; CELL MEMBRANE FLUIDITY; CELL MEMBRANE PERMEABILITY; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DRUG UPTAKE; GLIOMA CELL; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPID MEMBRANE; PHENOTYPE; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CHOLESTEROL ESTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLIOMA; GLUTATHIONE; HUMANS; MEMBRANE LIPIDS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; TECHNETIUM TC 99M SESTAMIBI;

EID: 4644316512     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.411     Document Type: Article

References (36)

1. Borst P, Evers R, Kool M, et al. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347.
2. Kvackajova-Kisucka J, Barancik M, Breier A. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen Physiol Biophys 2001;20:215.
3. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance- associated protein, MRP. Eur J Cancer 1996;32A:945.
4. Loe DW, Almquist KC, Deeley RG, et al. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675.
5. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione. Cancer Res 1998;58:5130.
6. Leier I, Jedlitschky G, Buchler M, et al. Identification of the biosynthetic leukotriene C4 export pump in murine mastocytoma cells as a homolog of the multidrug-resistance protein. Eur J Biochem 1996;242:201.
7. Leier I, Hummel-Eisenbeiss J, Cui Y, et al. ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 2000;57:1636.
8. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1.
9. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 2000;1486:128.
10. Hendrikse NH, Franssen EJ, van der Graaf WT, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283.
11. Kabasakal L, Ozker K, Hayward M, et al. Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med 1996;23:568.
12. Perek N, Prevot N, Koumanov F, et al. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000;27:299.
13. Perek N, Koumanov F, Denoyer D, et al. Modulation of the multidrug resistance of glioma by glutathione levels depletion-interaction with Tc-99M-sestamibi and Tc-99M-tetrofosmin. Cancer Biother Radiopharm 2002;17:291.
14. Vergote J, Moretti JL, de Vries EG, et al. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998;252:140.
15. Vandeputte C, Guizon I, Genestie-Denis I, et al. Microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: Performance study of a new miniaturized protocol. Cell Biol Toxicol 1994;10:415.
16. Cordobes MD, Starzec A, Delmon-Moingeon L, et al. Technetium-99m- sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286.
17. Sharom FJ. The P-glycoprotein efflux pump: How does it transport drugs? J Membr Biol 1997;160:161.
18. Ballinger JR, Hua HA, Berry BW, et al. "Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253.
19. Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function. Biochemistry 1997;36:10959.
20. Pallares-Trujillo J, Lopez-Soriano FJ, Argiles JM. Lipids: A key role in multidrug resistance? [review]. Int J Oncol 2000;16:783.
21. Campanella R. Membrane lipids modifications in human gliomas of different degree of malignancy. J Neurosurg Sci 1992;36:11.
22. Perek N, Denoyer D. The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection. Curr Drug Metab 2002;3:97.
23. Abe T, Mori T, Wakabayashi Y, et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 1998;40:11.
24. Homolya L, Vradi A, Sardaki B. Multidrug resistance associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003;17:103.
25. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998;20:931.
26. Utsunomiya K, Ballinger JR, Piquette-Miller M, et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27:1786.
27. Muzzammil T, Moore MJ, Ballinger JR. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. Cancer Biother Radiopharm 2000;15:339.
28. Li XF, Kinuya S, Yokoyama K, et al. Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): Comparison between a leukemia cell line with high MRP gene expression and its parental cell line. Cancer Biother Radiopharm 2001;16:17.
29. Perek N, Denoyer D, Dubois F, et al. Malignant gliomas display altered plasma membrane potential and pH regulation-interaction with Tc-99m-MIBI and Tc-99m-tetrofosmin uptakes. Gen Physiol Biophys 2002;21:381.
30. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995;228:1020.
31. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999;259:18.
32. Madesh M, Benard O, Balasubramanian KA. Glutathione modulates lipid composition of human colon derived HT-29 cells. Int J Biochem Cell Biol 1998;30:1345.
33. Santini MT, Romano R, Rainaldi G, et al. The relationship between 1H-NMR mobile lipid intensity and cholesterol in two human tumor multidrug resistant cell lines (MCF-7 and LoVo). Biochim Blophys Acta 2001;1531:111.
34. Pani A, Batetta B, Putzolu M, et al. MDR1, cholesterol certification and cell growth: A comparative study in normal and multidrug-resistant KB cell lines. Cell Mol Life Sci 2000;57:1094.
35. Luker GD, Nilsson KR, Covey DF, et al. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 1999;274:6979.
36. 18F-fluorodeoxyglucose. J Neurooncol 2000;46:63.